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ABSTRACT
Context: Hepatitis delta virus (HDV) leads to the most severe form of chronic viral hepatitis. 
Objectives: To determine the prevalence of HDV and create pooled estimations of possible 
risk factors, a systematic review was conducted to collect all epidemiological studies on 
HDV among chronic hepatitis B patients in Iran.
Data Sources: In this systematic review, databases such as pubMed, embase, ISI, Google 
scholar, and Iranian databases (MagIran, Iranmedex, and SID) were searched. 
Study Selection: Studies that clearly stated information about the number of HBsAg positive 
patients infected with HDV were selected.  
Data Extraction: The name of the city, the author’s name, year of study, HDV detection meth-
od, sample size, HBsAg positive frequency, mean age, total prevalence of HDV, and risk fac-
tors were extracted.
Results: The pooled HDV prevalence was 7.8% (95% CI: 5.89 - 9.71). In the survey-data analysis, 
HDV prevalence was 6.61%. HDV prevalence was 30.47% (95% CI: 9.76 to 51.19), 14.4% (95% CI: 
7.72 to 21.07), and 4.94% (95% CI: 3.73 to 6.15) in cirrhotic, chronic-hepatitis, and inactive-
carrier patients, respectively. pooled oRs were calculated for several factors common to Ira-
nian HBsAg-positive patients, including history of blood transfusion [oR: 1.1 (95% CI: 0.40 
to 2.98)], intravenous drug abuse [oR: 1.6 (95% CI: 0.78 to 3.21)], previous hemodialysis [oR: 
1.72 (95% CI: 0.79 to 3.76)], and HBeAg-positive status [oR: 1.26 (95% CI: 0.66 to 2.4)].
Conclusions: The prevalence of HDV is less common in Iran than in endemic regions such 
as Italy and Turkey; however, it is a severe form of hepatitis in HBsAg-positive patients. The 
most probable route of HDV transmission is hematologic, which suggests the importance 
of blood screening for HDV, especially in groups with numerous blood transfusions.
  Please cite this paper as: 
Amini n, Alavian SM,  Kabir A, Saiedi Hosseini SY, Aalaei-Andabili SH. Clinical Features and Seroepidemiology of Anti-HDV Antibody in 
patients With Chronic Hepatitis B Virus Infection in Iran: A Meta-Analysis. Hepat Mon. 2011; 11(12): 960-7. DoI: 10.5812/kowsar.1735143X.805
 Implication for health policy/practice/research/medical education:
This article is a collection of epidemiological studies on HDV in chronic hepatitis B patients in Iran. Study of the present article is 
highly recommended to hepatologists, gastroenterologists, virologists and epidemiologists.
Copyright  c 2011 Kowsar M. P. Co. All rights reserved. 
1. Context
Delta hepatitis infection leads to the most threatening 
form of chronic viral hepatitis, which can cause cirrhosis, 
fibrosis, and hepatocellular carcinoma (HCC) (1-3). More-
over, response to therapy is different and less satisfactory 
in  patients  with  hepatitis  delta  virus  (HDV)  infection 961 Clinical Features and Seroepidemiology of Anti-HDV Antibody
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than hepatitis B virus (HBV) monoinfection (4). It is esti-
mated that 15 to 20 million HBV patients are positive for 
anti-HDV antibody (5). The HDV incidence has declined 
in endemic countries in Western europe such as Italy (6). 
Hence, HDV persists as an applicable cause of morbidity 
in eastern europe and the Mediterranean basin (7, 8). In 
Iran, as a country located in the Mediterranean basin, the 
prevalence of HBsAg carrier is 2.14%, according to a recent 
review (9). Different rates of HDV infection among HB-
sAg-positive patients have been reported from Iran. The 
first report on this issue was described by Malekzadeh et 
al. in asymptomatic hepatitis B carriers in Shiraz (South 
of Iran), in which HDV prevalence was 13.9% (10), but re-
cent studies have shown that HDV rates varied from 0% in 
northern Iran (11) to 20% in southern Iran (12).
2. Objectives
To provide a clear estimate of HDV prevalence in Iran 
and address a gap in the field’s knowledge, we designed 
a  systematic  review  to  collect  all  respective  epidemio-
logical studies conducted in Iran about HDV in chronic 
hepatitis B patients. The prevalence of HDV was analyzed 
separately in the setting of chronic hepatitis, liver cirrho-
sis, HCC, and inactive carriers to show the effects of HDV 
on hepatitis progression. We investigated regional differ-
ences as well as potential chronological changes to ana-
lyze epidemiological changes of hepatitis D in various 
parts of Iran. pooled estimations for each possible risk 
factor, especially in high-risk groups, were calculated to 
identify the most important routes of HDV transmission.
3. Data Sources
The authors reviewed studies and evaluated the preva-
lence of HDV infection in HBsAg positive cases. The out-
comes considered in this review were the prevalence and 
risk factors of HDV infection.
one  author  (n.A.)  conducted  an  electronic  literature 
search through Scopus, ISI, Google scholar, and three 
Medline database engines—pubMed, embase, and ovid—
using different combinations of the word Iran and the 
key words “hepatitis D, Delta antigen, HDV, and hepatitis 
delta virus    ”. Iranian databases, including MagIran, Iran-
Medex, and SID, were also searched with relevant english 
and persian key words. At the time when these searches 
were  conducted,  the  databases  were  limited  to  pub-
lished and unpublished information up to and includ-
ing December 2010. Search sensitivity was checked by 
considering duplicated papers. If the full text of articles 
were not accessible, an e-mail was sent to the author. If 
no response was received after one month, the abstract 
was used to extract data (except for articles with no infor-
mative abstracts, which were omitted).
4. Study Selections
only studies that clearly stated information about the 
numbers of HBsAg-positive patients infected with HDV 
were selected. Studies in which all patients had acute 
hepatitis B (13-15) were excluded because the pattern of 
HDV is different in chronic and acute hepatitis. Investiga-
tors also excluded articles that were about the genotypes 
of HDV. The names of the authors and journals did not 
impact exclusion.
4.1. Assessment of Study Quality
A critical appraisal (CA) was conducted using the epible 
checklist (16) by three investigators (nA, SH SY, and AA 
SH) to evaluate the adequacy of sample size, research de-
sign, data collection, and presentation of results. If the 
investigators’  scores  were  not  close,  they  did  conduct 
another CA together again. Based on the total CA score, 
articles were divided into low (< 40%), moderate (40 to 
70%), and high (> 70%) quality. Low-quality papers were 
not included in the main analysis but were included in 
subgroup analyses.
5. Data Extraction
Data extraction was completed by three investigators 
(nA, SH SY, and AA SH) and rechecked by one of them 
(nA). Information was entered into Microsoft office ex-
cel 2007. The name of the city the author’s name, year of 
study,  HDV-detection  method,  sample  size,  HBsAg-pos-
itive frequency, mean age, and total prevalence of HDV 
were extracted. Moreover, standard errors (Se) were cal-
culated as Se = √ (p × [1-p] / n), where p = prevalence and 
n = sample size. HDV prevalence was extracted in differ-
ent subgroups consisting of cirrhotic patients, inactive 
carriers, chronic hepatitis patients, and male and female 
participants.
5.1. Statistical Analysis
A 95% CI of the seroprevalence of anti-HDV antibody 
was  computed  for  each  of  the  included  studies  using 
the approximate normal distribution model. The sum-
mary estimate of HDV prevalence was calculated as an 
average of the individual study results weighted by the 
inverse of their variances using fix/random models (Der-
Simonian and Laird) based on the heterogeneity test re-
sult using Q, I-squared and Tau-squared statistics. Due 
to the low power of this test, a minimum cut-off P value 
of 0.1 was established as a threshold of heterogeneity. I-
squared lies between 0% and 100% and heterogeneity in-
creases with increasing of I-squared value. Because few 
articles were available on some subgroups, Tau-squared 
is more suitable because it is not influenced by the num-
ber of studies. The results were expressed in geographic 
maps using Arc View 3.2 software (eSRI Inc., new York). 
For provinces with more than one study, the pooled es-
timation  of  anti-HDV  prevalence  was  computed  using 
the meta command, and then a survey-data analysis was 
used  to  estimate  more  accurate  HDV-infection  preva-
lence considering the weight of each city (17), which was 
calculated as the ratio of the city’s HBV population to the 
study’s sample size. The HBV population was calculated 
for each city by multiplying the city population (17) by 962 Clinical Features and Seroepidemiology of Anti-HDV Antibody
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the HBV-prevalence estimate (9). The same method was 
used to calculate HDV prevalence for both genders.
Subgroup analyses were designed according to disease 
patterns (cirrhotic, chronic hepatitis, and inactive car-
riers) and quality assessment scores (good and moder-
ate).  An  overall  meta-analysis  was  performed  for  each 
risk  factor  to  determine  whether  the  factor  increased 
HDV prevalence. The available data were used to calcu-
late or confirm the unadjusted odds ratio (oR). Risk fac-
tors, without complete data to calculate their oR, were 
omitted. To make pooled estimates, the authors used the 
“metan”  command  to  compute  point-estimation  oRs 
with a 95% CI for each risk factor. The analysis was per-
formed with STATA 11 software (STATA Corp. Lp).
6. Results
6.1. Studies
ninety-six articles were found in the literature review, 
40 of which (4, 10-13, 15, 18-49) were potentially related 
to HDV prevalence in Iran. The detailed search process is 
demonstrated in Diagram 1. Investigators sent an e-mail 
to the authors of four articles to obtain full text that was 
not available in the online databases (24, 44, 46, 48). only 
two authors (24, 44) responded within one month. Af-
ter filtering the studies based on the inclusion criteria 
explained above, 19 studies were identified as assessing 
the prevalence of HDV infection in Iran. out of these, 
four studies were conducted in Tehran (19, 22, 35, 38), two 
studies in Shiraz and (10, 45) Hamedan (21, 23), and 1 each 
in the cities of Shahrekord (28), Mashhad (32), Khuzestan 
(33), Isfahan (24), Sari (11), Golestan (39), Babol (34), Bush-
ehr (12), Kerman (49), and Tabriz (41). Additionally, one 
study was carried out in both Tehran and Tabriz (44) (Ta-
ble 1). All of the studies in this report were based on cross-
sectional  study  designs  conducted  between  1983  and 
2009, and the sample sizes ranged from 16 to 1,725. The 
ages of the study subjects ranged from 24 to 43. All stud-
ies measured anti-HDV with individual patients’ serums.
6.2. HDV Infection Prevalence
Reported HDV prevalence varied widely, from 0% in Sari 
(11) to 20% in Bushehr (12). Based on the heterogeneity 
tests (Q = 20,967.40 df = 18, P <.001; I-squared = 99.9%), 
a  random  model  was  considered.  Furthermore,  Tau-
squared indicated a variance of 18 between studies. The 
point estimation of HDV prevalence among 5,700 HBsAg-
positive patients from 13 cities in Iran was 7.8% (95% CI: 
5.89 - 9.71) from 1983 to 2009. According to the survey-data 
analysis, the HDV prevalence for each city was weighted 
using the HBV prevalence of the province’s population 
divided by the sample size (Table 1). The weighted mean 
prevalence of HDV infection calculated from 4,853 partic-
ipants was 6.61% (95% CI: 6.59 - 6.63). The total population 
of the cities considered in this survey was about 44% of 
the total population of Iran.
6.3. HDV Prevalence in Cirrhotic, Chronic-Hepatitis, 
Inactive-Carrier Patients
one source of heterogeneity was the different target 
populations in the studies. Therefore, the point esti-
mations  were  broken  into  three  subgroups:  cirrhotic, 
chronic-hepatitis, and inactive-carrier patients. There 
were 198 patients in the cirrhotic and HCC groups (4 arti-
cles: 4, 12, 33, 39), and the pooled estimation in this group 
was 30.47% (95% CI: 9.76 - 51.19). In chronic hepatitis group 
among 1,114 patients, the HDV prevalence in the random 
model was 14.4% (95% CI: 7.72 - 21.07; 7 articles: 19, 21, 33, 
38, 44, 45, 49).In 4,372 inactive carrier patients, the HDV 
prevalence was 4.94 % (95% CI: 3.73 - 6.15; 15 articles: (10, 11, 
19, 21-24, 28, 33-35, 38, 39, 41, 44) (Figure 1).
6.4. HDV Prevalence According to Diﬀerent Article Qual-
ity
The subgroup analyses depended on the quality of the 
studies. The HDV prevalence in articles (21, 23, 24, 33, 45, 
48), which had good quality scores was 7.15% (95% CI: 3.14 
to 11.14). In papers with moderate quality scores, the HDV 
prevalence was 8.09% (95% CI: 6.02 - 10.15). In low-quality 
studies,  the  HDV  prevalence  was  5.04%  (95%  CI:  -4.65  - 
14.75).
6.5. Gender Subgroup Analysis
The pooled estimations for women and men were cal-
culated separately using a survey-data-analysis method. 
The prevalence of HDV was estimated at 8.63% (95% CI: 
8.53 - 8.73) among 2,644 men and 5.34% (95% CI: 5.26 - 5.44) 
among 1,390 women.
6.6. Risk Factors
Ten articles (19, 21, 22, 24, 34, 35, 38, 39, 41, 45) mentioned 
risk factors. point estimations were calculated for factors 
such as history of blood transfusion, intravenous drug 
abuse, and hemodialysis and HBeAg positive serology. 
Table 2 demonstrates the relationship between different 
risk factors and anti-HDV serology.
7. Conclusions
According to our results, the overall estimation of HDV 
seropositivity in Iran is about 6.61% in HBsAg positive 
patients. The estimates were also run for asymptomatic 
and symptomatic HBsAg-positive patients. In our find-
ings, the overall estimation in the asymptomatic group 
was about 5%, and the time trend did not follow a rec-
ognizable  pattern.  Without  considering  outliers,  the 
HDV prevalence moved closer to 5%. The HDV prevalence 
among symptomatic HBsAg-positive patients was about 
14.5%, and it has been increasing over the years. The in-
crease in HDV prevalence among symptomatic HBsAg-
positive is different from the reports of declining cases in 
Italy (50), Spain (51), Taiwan (52), and Turkey (53). The de-
clining incidence rates in these countries may be related 
to better detection. In addition, the HDV-infection rate in 
the Iranian population is lower in comparison with oth-963 Clinical Features and Seroepidemiology of Anti-HDV Antibody
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er countries in the eastern Mediterranean Region (7, 54), 
and it is nearer to the rates in European and East Asian 
countries (Table 3).
HDV is more common in the south of Iran than in the 
north. However, HBV prevalence is higher in the north 
(9). The difference in HDV rates may be due to factors that 
have an impact on HDV acquisition such as the generally 
lower socioeconomic status in south of Iran. Moreover, 
we have scarce data about HBV and HDV prevalence rates 
in southern Iran (Figure 2).
our findings show that HDV is more common among 
cirrhotic and HCC patients. In a retrospective study in 
european patients with HBV-related cirrhosis, Fattovich 
et al. (54) found that the risk of HCC increased 3 times 
in HDV patients. In another study, during 233 months of 
follow-up (3), 82% and 15% of chronic HDV patients devel-
oped cirrhosis and HCC. This finding indicates that HDV 
causes a severe form of chronic hepatitis in comparison 
with HBV monoinfection. The longer history and more 
severe condition cause a higher rate of anti-HDV anti-
body, which is in line with previous studies.
In our study, the prevalence of HDV was higher in males 
(8.63%)  than  in  females  (5.34%).  Blood  transfusion  was 
generally more common in women, but we could not 
Study (Investigation Year) OR 95% CI Weighting Score Pooled Estimation (95% CI)
Blood transfusion 1.1 (0.40- 2.98)
Alizadeh et al. (2002-2007) (21)  0.43 0.05-3.73 0.84
Taghavi et al. (2003-2004) (45)  0.62 0.07-5.4 0.83
Alavian et al. (2001-2004) (19) 2.4 0.64-9.1 2.18
HBeAg positive 1.26 (0.66-2.4)
Ataei et al. (2009) (24)  0.72 0.15-3.4 1.56
Alizadeh et al. (2002-2007) (21)  2.2 0.66-7.22 2.70
Hassanjani Roshan et al. (2000-2002) (34) 5.1 1.47-18.33 2.42
Rezvan et al. (1986-1988) (38)  0.83 0.025-0.27 2.67
Amini Kafi-abad  et al. (2000) (22)  0
IDU 1.6 (0.78- 3.214)
Taghavi et al. (2003-2004) (45)  5.92 1.36-25.78 1.77
Jedari Seifi et al. (2006-2007) (41)  2.45 1- 6.03 4.75
Alizadeh et al. (2002-2007) (21)  2.06 0.35 - 11.92 1.25
Hemodialysis 1.72 (0.79- 3.76)
Karimi et al. (2000) (35) 24.79 5.56 -110.48 1.72
Jedari Seifi et al. (2006-07) (41)  1.7 0.68- 4.23 4.61
Taghavi et al. (2003-2004) (45)  0
    
Table 2. pooled HDV Risk Factors Among HBsAg positive patients in Iran, 1983-2008
Country/
Region
Target 
Population
Prevalence, % Sample Size Neighbors City 
in Iran
Prevalence in 
Neighbors, %
Degertekin H et al. 
(2008) (53)
Turkey/
middle east
Meta-analysis 27.1 6734  Tabriz  6
Jacobson IM et al. 
(1985) (56)
Afghanistan/
eMRo
high risk group and 
patients
28.6 362 Mashhad  9
Baig S et al.    
(2009) (57)
pakistan/
eMRo
patients 37 129 Kerman  10.7
Al Tarif I et al. 
(2004) (58)
Saudi Arabia/
eMRo
patients 8.6 19250 Khuzestan  11.5
Zaki S et al.       
(2010) (59)
Egypt/
eMRo
high risk group and 
patients
20 100 none -
Gaeta GB et al. 
(2003) (50)
Italy/
Europe
14 referral liver unites 8.3 834 none -
Chen X et al.  
(1998) (60)
China/
Asia
sample infected with 
HBV
7.72 2681 none -
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detect  this  factor’s  impact  on  HDV  prevalence.  How-
ever, other factors, such as a greater possibility of mul-
tiple partners, intravenous drug abuse, war injury, and a 
higher rate of HBV infection in men (9), can be explained 
as possible causes of this divergence. The results of this 
study showed that the main routes of transmission for 
HDV are blood and blood products; therefore, individu-
als with a history of transfusion, surgery, tattooing, war 
injury, dentistry interventions, endoscopy, hemodialysis, 
intravenous drug use, and patients with coagulation fac-
tor disorder are at risk of HDV. This route of transmission 
is more similar to Western europe and United states (55). 
The important groups in our review were hemodialysis 
patients and intravenous drug users. However, this as-
sociation was not statistically significant, which may be 
due to the unadjusted oRs to others factors. We did not 
have  enough  data  to  assess  interfamilial  and  sexually 
transmitted routes. In addition, the trend of the disease 
in HBeAg-positive patients with hepatitis D has not been 
well  established.  previous  articles  showed  HBeAg-posi-
tive rates of 15 to 30% among HDV patients (6). our find-
ings demonstrate that HDV is more common in patients 
who are HBeAg positive.
This review has some limitations, such as the lack of li-
brary and thesis searches. Additionally, data were avail-
able from 43% of provinces, and most of the data came 
from urban areas. The common method used for HDV 
detection was eLISA. Confirmation of ongoing HDV infec-
tion by pCR testing of HDV RnA was missing. The impact 
of this lack of information was that patients with and 
without  active  delta  infection  could  be  differentiated. 
The strongest part of this study was the use of a survey-
data analysis in addition to the usual meta commands to 
generalize the results to the whole population. Moreover, 
a critical appraisal allows for more accurate estimates. A 
quality subgroup analysis showed that the low-quality 
papers underestimated HDV prevalence.
In conclusion, the prevalence of HDV is less common 
in Iran than in endemic regions; however, this is a severe 
form of hepatitis in Iranian patients. The most probable 
route of HDV transmission is hematologic, which shows 
the importance of blood screening for HDV, especially in 
groups with numerous blood transfusions. Information 
is lacking from some provinces, and ongoing research 
is required to understand the effects of HDV infection 
on HBsAg-positive patients and its risk factors. More re-
search should be conducted on HDV to develop innovate 
strategies to control and diagnose this most severe form 
of viral hepatitis.
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